Linked Life Data

18297905

Source:http://linkedlifedata.com/resource/pubmed/id/18297905

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-2-26
pubmed:abstractText
Chemotherapy is one the therapeutic options in prostate cancer. Docetaxel once every three weeks is the current standard for castration-refractory disease with cancer-related symptoms. The docetaxel plus estramustine association is likely more active than docetaxel alone. Docetaxel is currently tested in early stages: first results of phase III trials are expected by 2009-2010.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0003-4401
pubmed:author
pubmed:issnType
Print
pubmed:volume
41 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S77-9
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
[Prostate cancer: future strategies for chemotherapy management].
pubmed:affiliation
Institut Gustave-Roussy, 14, avenue Paul-Vaillant-Couturier, 94800 Villejuif, France. karim.fizazi@igr.fr
pubmed:publicationType
Journal Article, English Abstract, Review